Alan S Maisel1, Kevin S Shah2, Denise Barnard3, Brian Jaski4, Geir Frivold5, John Marais6, Maged Azer7, Michael I Miyamoto8, Dawn Lombardo9, Damon Kelsay10, Navaid Iqbal3, Pam R Taub9, Ken Kupfer11, Elizabeth Lee3, Paul Clopton3, Michael Zile12, Barry Greenberg9. 1. Division of Cardiology, Veterans Affairs Medical Center, San Diego, California; Division of Cardiology, University of California, San Diego, California. Electronic address: amaisel@ucsd.edu. 2. Department of Medicine, University of California, San Diego, California. 3. Division of Cardiology, Veterans Affairs Medical Center, San Diego, California. 4. Division of Cardiology, San Diego Cardiac Center, San Diego, California. 5. Division of Cardiology, Veterans Affairs Loma Linda Healthcare System, Loma Linda, California. 6. Division of Cardiology, Care Clinical Research Corporation, Banning, California. 7. Division of Cardiology, St Joseph Hospital, Orange, California. 8. Division of Cardiology, Mission Internal Medical Group, St Joseph Heritage Health, Mission Viejo, California. 9. Division of Cardiology, University of California, San Diego, California. 10. Division of Cardiology, Desert Cardiology, Eisenhower Medical Center, Rancho Mirage, California. 11. Alere Inc., San Diego, California. 12. Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina.
Abstract
BACKGROUND: Heart failure is a common cause of hospitalization and can be divided into types with preserved and reduced ejection fraction (HFpEF and HFrEF, respectively). In this subanalysis of the HABIT (Heart Failure Assessment With BNP in the Home) trial, we examined the differences between home B-type natriuretic peptide (BNP) testing and weight monitoring in patients with HFpEF and with HFrEF before decompensation. METHODS AND RESULTS: This was a retrospective review of patients with HFpEF and HFrEF from the HABIT trial. The HFpEF patients compared with HFrEF patients were older and more obese and had lower baseline BNP values. Intra-individual BNP dispersion (spread of distribution over time) was greater in HFpEF than in HFrEF owing to rapid fluctuations (within 3 days). Slowly varying changes in BNP (estimated by a moving average) were equally predictive of ADHF risk in both HFpEF and HFrEF. However, in HFpEF, a rapid rise in BNP >200 pg/mL within 3 days was associated with an increased risk of acute decompensated heart failure (ADHF; hazard ratio 4.0), whereas a similar association was not observed in HFrEF. Weight gain ≥5 lb in 3 days had a high specificity but low sensitivity for ADHF in both HFpEF and HFrEF, whereas a lower threshold of ≥2 lb weight gain over 3 days in patients with HFpEF (but not HFrEF) was a moderately sensitive cutoff associated with decompensation (60% sensitivity). CONCLUSIONS: Patients with HFpEF and HFrEF have variations in their BNP and weight before decompensation. The rapid time scale behaves differently between the groups. In those with HFpEF, a 3-day period characterized by ≥2 lb weight gain and/or >200 pg/mL BNP rise was significantly associated with decompensation. Future prospective studies investigating different weight and BNP cutoffs for home monitoring of HFpEF and HFrEF patients should be performed to fully learn the value of BNP changes before clinical deompensation. Published by Elsevier Inc.
BACKGROUND:Heart failure is a common cause of hospitalization and can be divided into types with preserved and reduced ejection fraction (HFpEF and HFrEF, respectively). In this subanalysis of the HABIT (Heart Failure Assessment With BNP in the Home) trial, we examined the differences between home B-type natriuretic peptide (BNP) testing and weight monitoring in patients with HFpEF and with HFrEF before decompensation. METHODS AND RESULTS: This was a retrospective review of patients with HFpEF and HFrEF from the HABIT trial. The HFpEF patients compared with HFrEF patients were older and more obese and had lower baseline BNP values. Intra-individual BNP dispersion (spread of distribution over time) was greater in HFpEF than in HFrEF owing to rapid fluctuations (within 3 days). Slowly varying changes in BNP (estimated by a moving average) were equally predictive of ADHF risk in both HFpEF and HFrEF. However, in HFpEF, a rapid rise in BNP >200 pg/mL within 3 days was associated with an increased risk of acute decompensated heart failure (ADHF; hazard ratio 4.0), whereas a similar association was not observed in HFrEF. Weight gain ≥5 lb in 3 days had a high specificity but low sensitivity for ADHF in both HFpEF and HFrEF, whereas a lower threshold of ≥2 lb weight gain over 3 days in patients with HFpEF (but not HFrEF) was a moderately sensitive cutoff associated with decompensation (60% sensitivity). CONCLUSIONS:Patients with HFpEF and HFrEF have variations in their BNP and weight before decompensation. The rapid time scale behaves differently between the groups. In those with HFpEF, a 3-day period characterized by ≥2 lb weight gain and/or >200 pg/mL BNP rise was significantly associated with decompensation. Future prospective studies investigating different weight and BNP cutoffs for home monitoring of HFpEF and HFrEF patients should be performed to fully learn the value of BNP changes before clinical deompensation. Published by Elsevier Inc.
Entities:
Keywords:
Home monitoring; heart failure; natriuretic peptide; preserved ejection fraction
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Chris J Watson; Joe Gallagher; Mark Wilkinson; Adam Russell-Hallinan; Isaac Tea; Stephanie James; James O'Reilly; Eoin O'Connell; Shuaiwei Zhou; Mark Ledwidge; Ken McDonald Journal: J Transl Med Date: 2021-02-09 Impact factor: 5.531
Authors: A Faragli; D Abawi; C Quinn; M Cvetkovic; T Schlabs; E Tahirovic; H-D Düngen; B Pieske; S Kelle; F Edelmann; Alessio Alogna Journal: Heart Fail Rev Date: 2021-09 Impact factor: 4.214
Authors: Sean P Collins; Michael Thorn; Richard M Nowak; Phillip D Levy; Gregory J Fermann; Brian C Hiestand; Tillman Douglas Cowart; Robert P Venuti; William R Hiatt; ShiYin Foo; Peter S Pang Journal: J Clin Med Date: 2017-09-11 Impact factor: 4.241